Stryker Corp. (0R2S)
London Exchange · UK · prices in USD · close of 19 Oct 2026
Key indicators
| Last close | USD 300.11 |
|---|---|
| 52-week range | 156.82 – 392.18 |
| Return, 1 month / 3 months | +8.7% / −5.5% |
| Return, 1 year / 3 years | −18.5% / +14.5% |
| Trend | Below its 200-day average |
| RSI (14) | 61 |
| Volatility (1 year) | 112.6% |
| Worst drawdown (1 year) | -59.5% |
| Average daily value traded | 0.46M USD |
| Dividend yield | 1.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Stryker Corp. is a medical technology company that designs and makes orthopaedic implants, including hip and knee replacements, along with surgical equipment and instruments used in operating rooms. It also supplies hospital beds, stretchers and emergency medical products. Its customers are hospitals, surgeons and healthcare providers, and the company is based in Kalamazoo, Michigan, in the United States.
Stryker Corp. trades under the code 0R2S on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Stryker Corp. (0R2S) trades on the London Exchange in UK. It last closed at USD 300.11 on 19 October 2026.
Its price-based Market X-Ray is 29 out of 100 (a weak price profile), ranking 3,115 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 18.5% and over the last three months it fell 5.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 32 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -7.5% | ||
| From 52-week high | -23.2% | ||
| Momentum | 28 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -5.5% | ||
| 6-month return | -11.8% | ||
| 12-month return, skipping the last month | -25.0% | ||
| Stability (higher is calmer) | 9 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 112.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -59.5% | ||
| Liquidity | 45 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.46M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 52 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.2% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +6.6% |
|---|---|
| 1 month | +8.7% |
| 3 months | −5.5% |
| 6 months | −11.8% |
| 1 year | −18.5% |
| 3 years | +14.5% |
| 5 years | +16.7% |
Signals
| 50-day / 200-day average | 300.15 / 324.60 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 12.35 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Sep 2026 | USD 0.8800 |
| 29 Jun 2026 | USD 0.8800 |
| 30 Mar 2026 | USD 0.8800 |
| 30 Dec 2025 | USD 0.8800 |
| 29 Sep 2025 | USD 0.8400 |
| 27 Jun 2025 | USD 0.8400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.